AU2749697A - Use of prolactin as a tgf-beta antagonist - Google Patents
Use of prolactin as a tgf-beta antagonistInfo
- Publication number
- AU2749697A AU2749697A AU27496/97A AU2749697A AU2749697A AU 2749697 A AU2749697 A AU 2749697A AU 27496/97 A AU27496/97 A AU 27496/97A AU 2749697 A AU2749697 A AU 2749697A AU 2749697 A AU2749697 A AU 2749697A
- Authority
- AU
- Australia
- Prior art keywords
- prolactin
- tgf
- beta antagonist
- antagonist
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1649296P | 1996-04-30 | 1996-04-30 | |
US60016492 | 1996-04-30 | ||
PCT/US1997/007310 WO1997040848A1 (en) | 1996-04-30 | 1997-04-30 | Use of prolactin as a tgf-beta antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2749697A true AU2749697A (en) | 1997-11-19 |
Family
ID=21777407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU27496/97A Abandoned AU2749697A (en) | 1996-04-30 | 1997-04-30 | Use of prolactin as a tgf-beta antagonist |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0921809A4 (en) |
JP (1) | JP2000510112A (en) |
AU (1) | AU2749697A (en) |
CA (1) | CA2232682A1 (en) |
WO (1) | WO1997040848A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2526705T3 (en) | 2005-10-25 | 2015-01-14 | The Johns Hopkins University | Methods and compositions for the treatment of Marfan syndrome and associated disorders |
EP1998810A4 (en) | 2006-03-13 | 2009-09-02 | Univ Johns Hopkins | Augmentation of endothelial thromboresistance |
EP2918288B1 (en) | 2006-10-03 | 2017-08-16 | Genzyme Corporation | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
SI2835053T1 (en) | 2010-03-12 | 2016-09-30 | Genzyme Corporation | Combination therapy for treating breast cancer |
WO2012090997A1 (en) | 2010-12-27 | 2012-07-05 | 京都府公立大学法人 | iPS CELLS AND METHOD FOR GENERATING SAME |
US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
IN2014DN03049A (en) | 2011-10-26 | 2015-05-15 | Seattle Childrens Res Inst | |
EP2799537B1 (en) | 2011-12-28 | 2021-09-22 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
WO2015064768A1 (en) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU700104B2 (en) * | 1994-02-14 | 1998-12-24 | Genzyme Corporation | Prolactin as a vaccine adjuvant |
-
1997
- 1997-04-30 CA CA002232682A patent/CA2232682A1/en not_active Abandoned
- 1997-04-30 WO PCT/US1997/007310 patent/WO1997040848A1/en not_active Application Discontinuation
- 1997-04-30 JP JP09539206A patent/JP2000510112A/en active Pending
- 1997-04-30 AU AU27496/97A patent/AU2749697A/en not_active Abandoned
- 1997-04-30 EP EP97921467A patent/EP0921809A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2000510112A (en) | 2000-08-08 |
EP0921809A1 (en) | 1999-06-16 |
WO1997040848A1 (en) | 1997-11-06 |
EP0921809A4 (en) | 2001-10-24 |
CA2232682A1 (en) | 1997-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4594497A (en) | Set of tools for use un urethropexy procedures | |
AU3899997A (en) | Muscarinic antagonists | |
AU4945097A (en) | Thienopyrimidines having PDE V-inhibiting action | |
AU1640097A (en) | Extended release formulation | |
AU2630697A (en) | Connection base | |
AU4327197A (en) | Chuck | |
AU3550197A (en) | Syringes | |
AU3879197A (en) | Extensible indexing | |
AU3044197A (en) | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists | |
AU4791797A (en) | 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors | |
AU2438297A (en) | Combinations of angiostatic compounds | |
AU2186797A (en) | Pharmaceutically useful compounds | |
AU4340497A (en) | Golf accessory | |
AU4931693A (en) | Ibuprofen-h2 antagonist combinations | |
AU2749697A (en) | Use of prolactin as a tgf-beta antagonist | |
AU3123697A (en) | Angiostatic compounds | |
AU2413297A (en) | Crystalline metallophosphates | |
AU2047397A (en) | Crystalline metallophosphates | |
AU5423298A (en) | Novel compounds | |
AU1846397A (en) | Prolactin antagonists and uses thereof | |
AU3173597A (en) | Antineurodegenerative ergoline derivatives | |
AU3711697A (en) | Novel compounds | |
AU2786297A (en) | Virginiamycin mixture | |
AU5228198A (en) | Cd-rom interface | |
AU1601397A (en) | Famciclovir monohydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |